Cargando…

Non-small-cell lung cancer: how to manage BRAF-mutated disease

BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes 2 and 3) relies on their biological character...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guaitoli, Giorgia, Zullo, Lodovica, Tiseo, Marcello, Dankner, Matthew, Rose, April AN, Facchinetti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166262/ https://www.ncbi.nlm.nih.gov/pubmed/37168877 http://dx.doi.org/10.7573/dic.2022-11-3

Ejemplares similares

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
por: Guaitoli, Giorgia, et al.
Publicado: (2021)

Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’
por: Dankner, Matthew, et al.
Publicado: (2018)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Facchinetti, Francesco, et al.
Publicado: (2018)

First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
por: Facchinetti, Francesco, et al.
Publicado: (2020)

Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2019)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups
por: Perrone, Fabiana, et al.
Publicado: (2022)

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors
por: Leonetti, Alessandro, et al.
Publicado: (2020)

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
por: Gozzi, Fabrizio, et al.
Publicado: (2021)

Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation
por: Ambrosini-Spaltro, Andrea, et al.
Publicado: (2023)

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
por: Rossi, Giulio, et al.
Publicado: (2017)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
por: Eltayeb, Kamal, et al.
Publicado: (2022)

BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy
por: Li, Ming, et al.
Publicado: (2021)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
por: Gelsomino, Francesco, et al.
Publicado: (2021)

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
por: Lin, Quan, et al.
Publicado: (2019)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
por: Puri, Megha, et al.
Publicado: (2023)

Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics
por: Barabino, Emanuele, et al.
Publicado: (2022)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
por: Yan, Ningning, et al.
Publicado: (2022)

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer
por: Li, Hui, et al.
Publicado: (2022)

BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients
por: Ahn, Hyo Yeong, et al.
Publicado: (2023)

BRAF Inhibitors in Non-Small Cell Lung Cancer
por: Sforza, Vincenzo, et al.
Publicado: (2022)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
por: Pecci, Federica, et al.
Publicado: (2022)

Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial
por: Camerini, Andrea, et al.
Publicado: (2022)

BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2014)

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
por: Mu, Yuxin, et al.
Publicado: (2020)

Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation
por: Rittberg, Rebekah, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Systemic thromboembolism from a misdiagnosed non-bacterial thrombotic endocarditis in a patient with lung cancer: A case report
por: Perrone, Fabiana, et al.
Publicado: (2020)

Radiomic features of primary tumor by lung cancer stage: analysis in BRAF mutated non-small cell lung cancer
por: Padole, Atul, et al.
Publicado: (2020)

The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer
por: Zhang, Longyao, et al.
Publicado: (2022)

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer
por: Nicoś, Marcin, et al.
Publicado: (2015)

Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients
por: Peng, Panli, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qnhkf6fd8or36su4uq4l2udrp2